Figure 1.
Kaplan-Meier estimated overall survival and relapse-free survival with oral azacitidine vs placebo by baseline measurable residual disease status (MRD+ or MRD−). (A) Overall survival; (B) Relapse-free survival.
Kaplan-Meier estimated overall survival and relapse-free survival with oral azacitidine vs placebo by baseline measurable residual disease status (MRD+ or MRD−). (A) Overall survival; (B) Relapse-free survival.